Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Subcutaneous Hydrocortisone Infusion in CAH
NCT01859312Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- May 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydrocortisone in congenital adrenal hyperplasia (CAH), sponsored by National Institutes of Health. Primary endpoint: 17-Hydroxyprogesterone at 6 months. Started May 2013; status: completed.
02
Drugs
hydrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT01859312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859312.